BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 31634558)

  • 1. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
    Yang SY; Gegg M; Chau D; Schapira A
    Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.
    Yang SY; Beavan M; Chau KY; Taanman JW; Schapira AHV
    Stem Cell Reports; 2017 Mar; 8(3):728-742. PubMed ID: 28216145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
    Yang SY; Taanman JW; Gegg M; Schapira AHV
    Hum Mol Genet; 2022 Jul; 31(14):2396-2405. PubMed ID: 35179198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
    Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
    Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
    Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
    Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
    Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
    Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
    Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
    Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
    Kim MJ; Jeon S; Burbulla LF; Krainc D
    Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
    Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
    Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
    Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
    Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
    Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
    Prieto Huarcaya S; Drobny A; Marques ARA; Di Spiezio A; Dobert JP; Balta D; Werner C; Rizo T; Gallwitz L; Bub S; Stojkovska I; Belur NR; Fogh J; Mazzulli JR; Xiang W; Fulzele A; Dejung M; Sauer M; Winner B; Rose-John S; Arnold P; Saftig P; Zunke F
    Autophagy; 2022 May; 18(5):1127-1151. PubMed ID: 35287553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration.
    Polissidis A; Koronaiou E; Nikolopoulou G; Viel C; Nikatou M; Bogiongko M; Sardi SP; Xilouri M; Vekrellis K; Stefanis L
    Neurobiol Dis; 2022 Feb; 163():105612. PubMed ID: 34995756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
    Menozzi E; Toffoli M; Schapira AHV
    Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
    Parnetti L; Paciotti S; Eusebi P; Dardis A; Zampieri S; Chiasserini D; Tasegian A; Tambasco N; Bembi B; Calabresi P; Beccari T
    Mov Disord; 2017 Oct; 32(10):1423-1431. PubMed ID: 28843015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-type GBA1 increases the α-synuclein tetramer-monomer ratio, reduces lipid-rich aggregates, and attenuates motor and cognitive deficits in mice.
    Glajch KE; Moors TE; Chen Y; Bechade PA; Nam AY; Rajsombath MM; McCaffery TD; Dettmer U; Weihofen A; Hirst WD; Selkoe DJ; Nuber S
    Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.